AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02021396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: this arm of the study was interventional (splenic artery embolization)
Study NCT00146172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272
Study NCT00210106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablathermy
Study NCT04625270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766)
Description: avutometinib (VS-6766) monotherapy
Study NCT04625270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and defactinib
Description: avutometinib (VS-6766) and defactinib combination
Study NCT05216029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care
Study NCT05216029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: View oncology dashboard
Study NCT05216029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06104384 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral and supportive therapy
Description: Behavioral and supportive therapy
Study NCT01723592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Probiotics oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains,L.rhamnosus/ LbV96 (DSM 22560),L.jensenii /LbV 116 (DSM 22567),L.crispatus/ Lbv88 (DSM 22566),L.gasseri /LbV 150N (DSM 22583)
Study NCT01723592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral lactose placebo
Description: Placebo
Study NCT00838461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSD-016
Study NCT00439842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Failure Group Clinic Appointments
Description: Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
Study NCT04021940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ULOD
Description: ULOD
Study NCT04021940 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ULOD
Description: ULOD
Study NCT02656979 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprost
Description: Between measurements on day 1 and day 2, the subjects will receive a drop of latanoprost which is an IOP lowering drug once daily in one eye.
Study NCT02669732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a
Description: tablets
Study NCT02669732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets
Study NCT00967772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftopidil
Description: 25mg/ 50 mg/ 75mg dosage tablets
Study NCT02354989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate Response on first (VVI biventricular pacing)
Description: Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.
Study NCT02354989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate Response off first (VVI biventricular pacing)
Description: Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
Study NCT00587639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS Treatment
Description: Active rTMS treatment.
Study NCT01832987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-trimoxazole
Description: On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
Study NCT02877420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Technical Skills Training Curriculum
Study NCT02877420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Simulation Training Group
Study NCT03344250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR BATs with TMZ following SOC RT/TMZ
Description: Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.
Study NCT03344250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly EGFR BATs following SOC RT/TMZ
Description: Standard of care: 6 weeks of RT and TMZ Experimental: 8 weekly doses of EGFR BATs following SOC RT and TMZ
Study NCT03054389 — intervention group
Intervention type: OTHER
Intervention: Qualitative Interview - Participants/ Patients
Description: Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients
Study NCT03054389 — intervention group
Intervention type: OTHER
Intervention: Qualitative Interview - Investigators and Study Coordinators
Description: Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
Study NCT00697762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ-333369
Description: 200 mg tablet twice daily for 12 weeks
Study NCT00697762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ-333369
Description: 100 mg tablet twice daily for 12 weeks
Study NCT00697762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily for 12 weeks
Study NCT03530098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BoneAgeModel
Description: BoneAgeModel is an Artificial Intelligence tool that takes in a hand radiograph and gender, and outputs the skeletal (bone) age. The intervention involves using this tool as a factor in the clinical decision making process of the participating radiologists. The radiologist's decision will be considered final.
Study NCT04013139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CPET
Description: CPET
Study NCT01220622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: Administration of nimodipine 30mg tid for 6 months
Study NCT01220622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo 30mg tid for 6 months
Study NCT00838461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02260973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 (Triglyceride form)
Study NCT02260973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 (Triglyceride form)
Study NCT03231306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) are being treated on the pediatric MTD established by a phase I study (NCT02285439).
Study NCT02591758 — intervention group
Intervention type: DEVICE
Intervention: Hexoskin Vest
Description: The Hexoskin vest will be used at home to monitor the patient before and after the coronary angiography, during a treadmill test and during a home cardiac rehabilitation program.
Study NCT02591758 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cardiac rehabilitation program
Description: A 6 sessions home cardiac rehabilitation program will be prescribed to the patient 2 to 4 weeks after the coronary angiogram. Those sessions will take place under Hexoskin surveillance. One session will take place at our specialized institution and six sessions will take place at home over the time span of two to three weeks.
Study NCT02591758 — intervention group
Intervention type: OTHER
Intervention: Anxiety assessment as determined by the GAD-7
Description: Anxiety assessment using the General Anxiety Disorder (GAD-7) scale, at the end of the study, to see if the Hexoskin relieved the anxiety patients can feel at home when exercising after a percutaneous coronary intervention.
Study NCT02591758 — intervention group
Intervention type: OTHER
Intervention: Angina assessment with the angina diary, the SAQ and the SF-36
Study NCT02591758 — intervention group
Intervention type: OTHER
Intervention: Exercise stress test
Description: Using the RAMP protocol before and after the coronary intervention, under Hexoskin surveillance.
Study NCT02591758 — intervention group
Intervention type: OTHER
Intervention: Holter monitoring
Description: 24-hour Holter monitoring before and after the coronary angiogram with simultaneous Hexoskin reading.
Study NCT04470908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Single oral dose of 320 mg
Study NCT04470908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Oral dose of 300 mg once daily
Study NCT00518986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 200 mg/day
Study NCT01352442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcuFocus Corneal Inlay ACI 7000PDT
Description: corneal inlay
Study NCT00811005 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 8-methoxypsoralen or 5- methoxypsoralen
Description: Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet.
Study NCT00518986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01442675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®
Description: 0.5 mL, Intramuscular
Study NCT05447637 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Invitae multi-cancer gene panel
Description: Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.
Study NCT02324894 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI screening
Description: Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
Study NCT00680381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MTI, Minimal Transitional Intervention
Description: Following 12 weeks of Functional Family Therapy (FFT), semi-weekly phone calls from a therapist for eight weeks.
Study NCT00680381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GTI, Group Transitional Intervention
Description: Following 12 weeks of FFT, weekly one-hour sessions of group therapy for eight weeks.
Study NCT00680381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STI, Systems Transitions Intervention
Description: Following 12 weeks of FFT, an individualized eight-week series of therapist meetings with the adolescent, family, police, teachers, coaches and others who can support the adolescent's reduced drug use.
Study NCT03750799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Whole body vibration was applied on the right lower extremity in the experimental group.
Study NCT03750799 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vibration
Description: Sham vibration was applied on the right lower extremity in the Control sham group
Study NCT03718013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: accelerated deep TMS
Description: subjects treated with deep TMS twice a day (6-8 hours between two applications), during 2 weeks
Study NCT03718013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard deep TMS
Description: standard deep TMS treatment: once a day, during 4 weeks
Study NCT00811005 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen or 5- methoxypsoralen
Description: Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet.
Study NCT00811005 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 8-methoxypsoralen or 5methoxypsoralen
Description: PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet.
Study NCT00811005 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen or 5methoxypsoralen
Description: PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet.
Study NCT05022108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha bisabolol gel
Description: Using alpha bisabolol gel with a concentration of 0.5%, 2,5% or 5% to treat sensitized area with histamine.
Study NCT04403971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine Oral Liquid Product
Description: The intervention group 1 received 10ml 0.12% chlorhexidine solution for oral rinse twice a day.
Study NCT04403971 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Listerine Oral Liquid Product
Description: The intervention group 2 received 10ml Listerine solution for oral rinse twice a day.
Study NCT04403971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Product
Description: The control group received 10ml normal saline for oral rinse twice a day.
Study NCT02359448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
Study NCT01321164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full Body UV Therapy System UV 7002 plus fumaric acid esters
Description: Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.~Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months
Study NCT01214811 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mepilex Border Ag
Description: Mepilex Border Ag may be left in place for up to seven days, depending on the condition.
Study NCT04921371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate® Cavity Protection Toothpaste
Description: Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
Study NCT04921371 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Colgate® Cavity Protection Toothpaste
Description: Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
Study NCT04921371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine® Cool Mint®
Description: Participants will use 20 mL of Listerine® Cool Mint® mouth rinse for 30 seconds after brushing twice daily.
Study NCT04921371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concept Curve Winter Series Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
Study NCT04921371 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Concept Curve Winter Series Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
Study NCT04921371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% Hydroalcohol Mouthrinse
Description: Participants will use 20 mL of 5% Hydroalcohol Mouthrinse for 30 seconds after brushing twice daily.
Study NCT04921371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthrinse Prototype 1
Description: Participants will use 20 mL of Mouthrinse Prototype 1 for 30 seconds after brushing twice daily.
Study NCT04921371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthrinse Prototype 2
Description: Participants will use 20 mL of Mouthrinse Prototype 2 for 30 seconds after brushing twice daily.
Study NCT04159844 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: URGOBD001
Description: Application with 50% overlapping
Study NCT04159844 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: URGOBD001 associated with wading
Description: Application with 50% overlapping in association with wading
Study NCT01321164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fumaric acid esters
Description: Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
Study NCT00995592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Philani nutrition intervention program (mentor mothers)
Description: Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
Study NCT04502381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled amp B deoxycholate+intravenous liposomal amp B
Description: Intravenous liposomal amphotericin B (beginning with 3mg/kg) along with inhaled amphotericin as below: Amp-B deoxycholate 50 mg (Amphotret™ Bharat serums and vaccines limited), will be dissolved in 10 mL distilled water. 2 mL of the reconstituted amphotericin B solution will be transferred into the drug chamber of a breath actuated nebulizer (Lupineb Ultra kit breath actuated nebulize which contains aeroclipse XL Reusable Breath Actuated Nebulizer and DeVilbiss 3655 compressor). 3 mL of distilled water is added to 2 mL of the reconstituted amphotericin B. The nebulization is continued till the chamber is emptied of the drug or the patient does not tolerate the therapy.~The first three doses of amphotericin B nebulization will be under the direct supervision of a physician. If tolerated, nebulization will be continued twice a day till tolerated or till response.The patient will complete a VAS score for cough after nebulization.
Study NCT04502381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous liposomal amphotericin B alone
Description: Intravenous liposomal amphotericin B (beginning with 3mg/kg, up to 5 mg/kg), with or without surgery or other antifungals as clinically indicated
Study NCT04502381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous liposomal amphotericin B alone
Description: Intravenous liposomal amphotericin B (beginning with 3mg/kg, up to 5 mg/kg), with or without surgery or other antifungals as clinically indicated
Study NCT01969916 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Regadenoson
Description: Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
Study NCT01617369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: 2.8% NaCl x 4ml via nebulizer
Study NCT01617369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline
Description: 2.8% NaCl x 4ml via nebulizer
Study NCT02666651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
Study NCT02666651 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
Study NCT02769338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement Program
Description: The Intervention is a QI Program that will include multiple components as described above.
Study NCT02924207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PATH electronic decision support tool
Description: PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.